A study co-led by a Johns Hopkins Children's Center clinician-researcher shows that adding text messaging and other electronic feedback to traditional in-clinic health counseling for parents about ...

A new study examining a large sample of privately insured patients with obesity found that use of drugs such as Ozempic and Wegovy as anti-obesity medications more than doubled from 2022 to 2023.

If you're overweight or you have obesity, losing 5% to 15% of your body weight can improve your heart health and lower your risk of type 2 diabetes. But losing weight can be hard to do.

Mounjaro, which is made by Lilly, is a glucagon-like peptide-1 (GLP-1) agonist, a family of medications that help manage blood sugar and are used to treat type 2 diabetes and obesity. Other GLP-1 ...

A study by Health Innovation Manchester and pharmaceutical firm Lilly will examine the “real-world effectiveness” of anti-obesity treatment Mounjaro, also known as tirzepatide, on weight loss ...

A study by Health Innovation Manchester and Lilly will examine the “real-world effectiveness” of anti-obesity treatment Mounjaro, also known as tirzepatide, on weight loss, diabetes prevention ...

“Pound for pound” assessment of anti-obesity medications, coverage policies, and financial considerations. Presented at: AMCP Nexus 2024; October 14-17, 2024; Las Vegas, NV.

The British government is planning to give weight-loss injections to obese people so they can be taken off sickness benefits and obliged to work. This remarkable scenario, like something from a ...

Young people taking anti-obesity medications are less likely to experience suicidal thoughts or make attempts on their lives, according to the latest study to analyse the potential psychiatric ...

A study by Health Innovation Manchester and Lilly will examine the “real-world effectiveness” of anti-obesity treatment Mounjaro, also known as tirzepatide, on weight loss, diabetes prevention ...

2024 — A new study has examined a large sample of privately insured patients with obesity and found that use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as anti-obesity medications ...